These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. Brown JM; Hanson GR; Fleckenstein AE J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904 [TBL] [Abstract][Full Text] [Related]
10. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. Hanson GR; Sandoval V; Riddle E; Fleckenstein AE Ann N Y Acad Sci; 2004 Oct; 1025():146-50. PubMed ID: 15542712 [TBL] [Abstract][Full Text] [Related]
11. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. Eyerman DJ; Yamamoto BK J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654 [TBL] [Abstract][Full Text] [Related]
12. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855 [TBL] [Abstract][Full Text] [Related]
13. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. Volz TJ; Hanson GR; Fleckenstein AE J Neurosci Methods; 2006 Jul; 155(1):109-15. PubMed ID: 16480775 [TBL] [Abstract][Full Text] [Related]
14. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Suzuki M; Desmond TJ; Albin RL; Frey KA Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403 [TBL] [Abstract][Full Text] [Related]
15. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease. Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803 [TBL] [Abstract][Full Text] [Related]
16. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813 [TBL] [Abstract][Full Text] [Related]
17. Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals. Nirenberg MJ; Chan J; Liu Y; Edwards RH; Pickel VM Synapse; 1997 Jun; 26(2):194-8. PubMed ID: 9131778 [TBL] [Abstract][Full Text] [Related]
18. PCB-induced inhibition of the vesicular monoamine transporter predicts reductions in synaptosomal dopamine content. Bemis JC; Seegal RF Toxicol Sci; 2004 Aug; 80(2):288-95. PubMed ID: 15115888 [TBL] [Abstract][Full Text] [Related]
19. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Tong J; Wilson AA; Boileau I; Houle S; Kish SJ Synapse; 2008 Nov; 62(11):873-6. PubMed ID: 18720517 [TBL] [Abstract][Full Text] [Related]
20. Selective alterations of gene expression in mice induced by MPTP. Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]